throbber
Apoptosis in Bone Marrow Biopsy Samples Involving Stromal and
`Hematopoietic Cells in 50 Patients With Myelodysplastic Syndromes
`
`By Azra Raza, Sefer Gezer, Suneel Mundle, Xue-Zhi Gao. Sairah Alvi, Raphael Borok, Shelby Rifkin, Amna litikhar,
`Vilasini Shetty, Agapi Parcharidou, Jerome Loew, Bridget Marcus, Zaineb Khan, Colette Chaney, John Showel,
`Stephanie Gregory, and Harvey Preisler
`
`Cell-cycle kinetics Were measured in situ after infusions of
`iododeoxyuridine and/or bromodeoxyuridine in 50 patients
`with myelodysplastic syndromes (MDS) and the median la-
`beling index in bone marrow lBMl biopsy samples was
`28.6%. Unfortunately, 26 of 50 patients showed that 275%
`of hematopoietic cells of all three lineages were undergoing
`programmed cell death (PCD) in their biopsy samples as
`shown by the in situ end labeling (ISEL) technique. Ten pa-
`tients had 113 and eight had 2/3 ISEL+ cells. Stromal cells
`were frequently ISEL* and often S-phase cells were also
`found to be simultaneously ISEL”. Nucleosomal DNA frag-
`ments as a ladder in agarose gel were present in BM aspi-
`
`HE MYELODYSPIASTIC syndromes (MDS) are a
`group of acquired hematopoietic disorders with evi-
`dence of trilineage dysplasia and an ~30% incidence of
`eventual
`transformation
`into
`acute myeloid leukemia
`(AML)."3 These are clonal disorders involving one or more
`clones,” and normal hematopoiesis has been shown to si—
`multaneously coexist in the majority of cases.6 Patients with
`evidence of “Abnormally Localized Immature Precursors"
`(ALlP) in their bone marrow (BM) biopsy samples tend to
`die earlier than ALIP—negative patients because of a rapid
`transformation into acute leukemia.7 Cytogenetic abnormali-
`ties cspecially involving chromosomes 5 and 7 are com-
`monly detected,R whereas ras-mutations signifying short sur-
`vival have been showed in ~10% to 40% patients.9 The
`disease is almost invariably fatal, and with the exception of
`BM transplantation, there is no known cure.l0
`An apparent paradox in MDS is that patients with these
`disorders have peripheral cytopcnias despite frequently hav-
`ing normo- or hypercellular BMs. One possible explanation
`for this contradictory finding may be that even though there
`are large numbers of cells in the BM, they are not exiting
`that companrncnt because they are undergoing premature
`programmed cell death (PCD). To examine this possibility,
`the present study was undertaken to define the incidence of
`PCD in the hematopoietic cells of MDS patients. Apoptosis
`is a gene-directed cellular self—destruction in which intracel-
`
`
`the
`From the Division of Hematology. Rush Cancer Institute,
`Department of Pathology, Rush-Presbylerian-SI Luke ’5 Medical
`Center, Chicago: and Northwest Community Hospital, Arlington
`Heights, IL.
`Suhmirled November 7, 1994; accepted February 9, 1995.
`Suppor/ed in part by a Grant No. (R01CA60085) from The Na-
`tional Cancer Institute.
`Addresr reprint requests to Azra Ruza. MD. Professor of Medi-
`cine, Director, Leukemia Program, Rush Cancer Institute, Rush-
`Presbyzerion-Sr Luke's Medical Center, 2242 W Harrison SI, Suite
`108, Chicago. IL 60612.
`The publication costs of this article were defrayed in part by page
`charge payment. This article must
`therefore be hereby marked
`“advertisement“ in accordance with 18 U.S.C. section [734 solely to
`indicate this fact.
`© 1995 by The American Society of Hematology.
`0006—4971/95/860] -0026$3.00/0
`
`268
`
`rates of four patients who showed high ISEL and were ab-
`sent in two who had no ISEL staining in biopsy samples,
`but only when DNA was extracted after a 4-hour in vitro
`incubation in complete medium. Therefore, laddering data
`confirmed the ISEL findings that the majority of hematopoi-
`etic cells in MDS are in early stages of PCD. We conclude
`that extensive intramedullary cell death may explain the par-
`adox of pancytopenia despite hypetcellular marrows in MDS
`patients. Investigating approaches that protect against PCD
`in some MDS subsets would be of interest.
`0 1995 by The American Society of Hematology.
`
`lular endonucleases initially cleave the DNA into inter-
`nucleosomal fragments (180 to 200 bp or their integral multi-
`ples).”’” This process, which begins with fragmentation of
`DNA, ends eventually with fragmentation of the nucleus and
`removal of the dead cell by macrophages. Although an end-
`stage karyorrliectic cell
`is easy to recognize under a light
`microscope,
`the earlier stages of PCD with limited DNA
`fragmentation and internucleosomal nicking cannot be mor—
`phologically identified. Thus, large numbers of cells may be
`undergoing apoptosis, yet there may be only a few cells in
`the morphologically identifiable karyorrhectic stage. Conse-
`quently, an accurate estimation of the incidence of PCD
`must include a precise quantitation of cells in early stages
`of apoptosis in addition to the obviously karyorrhectic cells.
`The conventional method of detecting typical “DNA lad-
`dering" by gel electrophoresis may not be able to provide
`this information because very little low molecular-weight
`DNA fragments are formed in cells that are in the earlier
`stages of PCD.‘5 The technique of in situ end labeling (ISEL)
`of fragmented DNA appears to bc a more reliable measure-
`ment of the early stages of apoptosis."’"“ Therefore, BM
`biopsy samples of 50 MDS patients were processed for ISEL.
`The results obtained showed an exceptionally high rate of
`apoptosis in the hematopoietic cells of all three lineages in
`these patients. These data confirmed our initial hypothesis
`that high intramedullary death of hematopoietic cells may
`be the biologic basis for the paradox of puncytopenia despite
`hypercellular marrows in MDS patients.
`
`MATERIALS AND METHODS
`
`Rates of hematopoietic cellular proliferation and apoptosis were
`examined in fifty patients with a confirmed diagnosis of MDS. Each
`patient received a l-hour infusion of bromo- and/or iododeoxyuri-
`dinc (BrdU and lUdR) at
`l00 myrn2 as per protocols MDS 86—
`l5 and/or MDS 90-02. Informed consent was obtained from every
`individual. The infusion protocols were approved by the local Institu-
`tional Review Board and the Food and Drug Administration and the
`drugs were provided by the National Cancer institute. Sums of these
`patients' results have also been reported in earlier sunbeam”
`
`Studies of Cellular Proliferation
`
`Immediately at the end of the second thymidinc analogue infusion,
`samples of BM aspirate (BM asp) and biopsy were obtained. The
`aspirates were used for the determination of durations of S—phase as
`
`Blood. Vol 86, No 1 (July 1), 1995: pp 268-276
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 1
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 1
`
`

`

`APOPTOSIS IN BM BIOPSY SAMPLES
`
`described before?“ The BM biopsy samples were embedded in
`plastic using glycol methacrylate. Air-dried 2-3-pm—thick sections
`were placed on Alcian Blue—coated coverslips and processed for the
`estimation of labeling indices using an anti-IUdeBrdU monoclonal
`antibody (MoAb) as described before?”
`
`Studies to Measure the Incidence of PCD or
`Apoptosis
`Two methods were used to measure the rale of apoptosis in these
`patients. The in siru end labeling (ISEL) of fragmented DNA as
`described by Wijsman et al“ was modified for use in plastic embed-
`ded biopsy samples for the detection of cells undergoing PCD. BM
`asps from six MDS patients, three AML patients, and two normal
`controls were examined for the presence of the typical ladder pattern
`in agarosc gels. Details of both methods are provided below.
`
`ISEL of Fragmented DNA
`Two-micrometer sections from the previously mentioned BM bi-
`opsy samples were obtained. The sections were rehydrated in dis-
`tilled water for 10 minutes and then incubated with freshly diluted
`3% hydrogen peroxide (H101) for 30 minutes. Specimens were thor-
`oughly rinsed in 0.15 mol/L phosphate buffer solution (PBS) (0.15
`mol/L sodium chloride [NaCl] in 0.1 mol/L phosphate buffer. pH
`7.5). Subsequently they were incubated with sodium chloride. so-
`dium citrate solution (SSC) (0.3 moi/L NaCl and 30 mmol/L Na-
`citrate. pH 7.0) at 80°C for 20 minutes followed by thorough washing
`with 0.15 mol/L PBS. The sections were next treated with prouase
`(1.0 mg/mL in 0.15 mol/L PBS, Calbiochcm. LaJolla. CA) at room
`temperature for 30 minutes. After this they were rinsed first in 0.15
`mol/L PBS and then in buffer A, pH 7.5 (50 mmol/L TRIS HCl, 5
`mmol/L MgClz, 10 mmol/L fi—mercaptoethanol and 0.005% bovine
`serum albumin [BSA], fraction V; Sigma Chemical Co. St Louis,
`MO). Sections were then incubated with ISEL solution prepared in
`buffer A (0.0] mmol/L deoxyadenosine triphosphate, deoxyguano—
`sine niphosphate, deoxycytidine hiphosphate) (Promega, Madison,
`WI), 0.00] mmol/L biotin-11 deoxyuridine triphosphate (Sigma),
`and 20 U/mL Escherichia coli DNA polymerase I (Promega) at 18°C
`for 2 hours, followed by washing with buffer A and later with 0.5
`mol/L PBS (0.5 mollL NaCl in 0.1 mol/L phosphate buffer, pH 7.5).
`The specimens were then incubated with avidin—bimin-horseradish
`peroxidase conjugate (Vectastain Elite ABC Kit-Vector, Burl.
`ingame, CA; diluted 1:25 in 0.5 mol/L PBS containing 1% BSA
`and 0.5% Tween 20). Finally. samples were stained using 0.04%
`3.3’-diaminobenzidine tetrahydrochloride diluted in 0.05 mol/L
`TRIS buffer, pH 7.5, with 0.015% of 30% 1'10; for 10 minutes and
`rinsed well with distilled water. The specimens were then mounted
`with Fluoromount G (Biotechnology Associate lnc, Birmingham,
`AL). Slides were left to dry overnight before estimation of PCD.
`
`Simultaneous Assessment of Cell Birth
`(Proliferation) and Cell Death (Apoptosis) From the
`Same Biopsy Sample Section Using Double-Labeling
`by ISEL and Anti-lUdr/BrdU MoAb
`For the double—labeling technique designed to simultaneously de—
`tect S-phase cells and PCD. sections were first processed for ISEL
`as described above, and then rinsed thoroughly in 0.5 moi/L TBS
`(0.5 mol/L NaCl in 0.05 mol/L TRIS buffer, pH7.5). Subsequently
`the sections were treated with 4 N HCl for 15 minutes, and the anti-
`IUdR/BrdU MoAb 3D9 (20-22) diluted 1:200 in 0.5 mollL TBS
`containing 0.25% Tween 20 for 60 minutes at room temperature,
`rabbit antimouse IgG (Dako, Carpenteria, CA) diluted 1:20 in 0.5
`mol/L TBS for 30 minutes and with mouse alkaline phosphatase—
`antialkaline phosphatase antibody (Dako, diluted 1:40 in 0.5 mol/L
`TBS) for 30 minutes. The sections were rinsed thoroughly with 0.5
`
`259
`
`mollL TBS after each of the above-mentioned incubations. Sections
`were then immersed in the following detection solution for 8 to 10
`minutes at 20°C. It contained Naphthol AS-MX phosphate (20 mg)
`freshly dissolved in 2 mL N.N-dimethylformamide. This was added
`to 100 mL 0.1 mol/L TRIS buffer, pH 8.2 followed by 0.1 mL 1
`mol/L Levamisole and 100 mg of Fast Blue BB salt (Sigma Chemical
`Co, St Louis, MO). The solution was stirred for 2 minutes and
`filtered before use. Sections were washed in distilled water and
`mounted with Fluoromount.
`
`Control Experiments for ISEL Technique
`Control experiments for ISEL technique included two types of
`controls: negative and positive.
`
`Negative Controls
`ISEL solution devoid of DNA polymerase was used on control
`samples as negative controls. These slides were universally negative.
`
`Positive Controls
`
`Positive controls included DNA laddering versus ISEL of frag-
`mented DNA, detection of apoptosis in BM biopsy samples obtained
`from newly diagnosed high-risk patients with AML. and detection
`of apoptosis in normal BM biopsy samples obtained from patients
`with non—Hodgkin’s lymphoma (NHL).
`HL—60 cells
`DNA laddering versus ISEL affragmented DNA.
`were treated with a topoisomerase inhibitor etoposide (VP 16) at a
`concentration of 35 ymol/UmL in RPMI 1640 medium containing
`20% fetal bovine serum (PBS). The control cells were incubated in
`the same medium without etoposide. The incubation was continued
`for 4 hours at 37°C in 5% C02. At the end of the incubation, each
`sample was divided into two aliquots. Cells from one aliquot were
`embedded in plastic. sectioned. and processed for ISEL to detennine
`the percentage of apoptotic cells, whereas the other aliquot was used
`for DNA extraction. The DNA so obtained was run on an agarose
`gel containing ethidium bromide.
`Detection ofapoptosis in BM biopsy samples obtainedfrom newly
`diagnosed high-risk patients with acute myeloid leukemia (AML).
`Twenty AML biopsy samples were processed for ISEL before stan-
`ing remission induction chemotherapy.
`Detection of apoptosis‘ in normal BM biopsy samples obtained
`from patienls with NHL Two NHL patients who had no BM
`involvement and whose BM biopsy samples were judged by hemato-
`pathologists to be indistinguishable from normal BM biopsy samples
`were also processed for ISEL technique to determine the incidence
`of apoptotic cell death.
`
`Interpretation of BM Biopsy Specimen Slide
`All slides were examined under a light microscope attached to a
`television screen. At least three different investigators were involved
`in the interpretation of each slide (A.R. being one of them every
`time).
`
`Proliferation Studies
`Immunohistochemical detection of lUdR- and/or BrdU—labeled S-
`phase cells was accomplished using either the anti-IUdR/BrdU
`MoAb 3D9 or the anti-BrdU MoAb Br-3. The nuclei ofcells engaged
`in DNA synthesis were stained dark-brown in single-label slides.
`The labeling index (Ll) was obtained by counting only the labeled
`myeloid cells as described before?“ Frequently erythroid islands
`as well as occasional megakaryocytes were also in S-phase and
`these were easily recognizable because of their unique morphologic
`appearance. These labeled erythroid and megakaryocytic cells and
`their unlabeled counterparts were excluded from the LI calculations.
`At least 2.000 cells from five different fields were counted.
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 2
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 2
`
`

`

`270
`
`PCD Studies by lSEL
`Coverslips processed for lSEL were mounted onto glass slides
`and examined on the television screen by a group of observers (AR
`was always present). The slides were first scanned under low power.
`lSEL‘ cells showed clear. punctate brown staining over their nuclei.
`often being most marked in the perinuclear area. Areas of apoptosis
`and PCD were identified if these were present in compartmentalized
`pockets. The following scoring system was used to approximately
`quantitate the incidence of PCD: absent. only an occasional lSEL+
`cell, definitely constituting 515% of all cells; low, up to one third
`of the biopsy sample containing lSEL‘ cells; intermediate, between
`one third and two thirds of the biopsy sample containing lSEL‘
`cells; high, 275% lSEL+ cells.
`
`Simultaneous Proliferation and PCD Studies
`In these double-labeled slides. the nuclei of S—phasc cells were
`stained blue, the nuclei of ISEL’ cells were stained brown and those
`S—phase cells that were also lSEL+ showed the presence of both
`brown and blue staining.
`
`Detection of DNA Laddering
`Detection of DNA laddering was performed on BM asp cells of
`six MDS and three AML patients as well as two BM asp samples
`that were completely normal (obtained from BM transplant donors).
`After density separation on FicolI-Hypaquc,
`l X 10‘I cells/ml. were
`incubated for 4 hours at 37°C in 5% CO; atmosphere and used
`for DNA extraction. Cells without the 4-hour incubation were also
`similarly used for DNA extraction. The reason for incubating cells
`over various time points before extracting DNA was as follows: Our
`hypothesis based on the lSEL data in BM biopsy samples was that
`most of the cells appeared to be in earlier stages of PCD with only
`low amounts of DNA damage that may not be sufficient to produce
`laddcring in gels. However, leaving the cells in complete medium
`over specified time points may be enough time for the cells to
`complete the process of apoptosis with generation of low molecular-
`weight DNA that would produce the typical DNA laddering. Thus,
`although initial experiments used a variety of time points (0,
`l. 2,
`3, and 4 hours) for in vitro incubation of cells in complete medium
`before DNA extraction, later experiments have used only the 0- and
`4-hour time points because they appear to be the two most informa-
`tive intervals.
`Briefly, the cells were washed in 0.1 mol/L PBS, pH 7.5 (0.1 mol/
`L NaCl in 0.1 mol/L PBS) to remove traces of medium, lyscd with
`guanidine isothiocyanate (GITC) at room temperature and layered
`on 5.7 mot/L cesium chloride (CsCl) gradient. After overnight cen—
`trifugation at 32,000 rpm, the DNA fraction at the interface of CsCl
`and GlTC was aspirated and pooled together with the RNA fraction
`from the bottom of CsCl gradient tube. Subsequently. this prepara-
`tion was treated with chilled 100% and 80% ethanol. incubated with
`Proteinase K (Boehringer Mannheim, Mannheim, Germany) and re-
`peatedly treated with phenol:chloroform:isoamyl alcohol mixture
`(2522421. Sigma) to remove proteins. DNA was then precipitated by
`adding Na-acetate (3 moi/L, pH 6.0) and double volume of chilled
`100% ethanol for 1 hour at -20°C. This DNA fraction was then
`treated with RNase concentration 1 ag/mL (final concentration 20
`ug/mL) and subjected to reextraction using phenol:chlorot‘orm:iso-
`amyl alcohol mixture followed by treatment with Na-acctae and
`chilled 100% ethanol as described earlier. Finally, the total DNA
`content in each sample was estimated by optical density at 260 nm
`and 5 /.tg DNA was loaded in 1.5% agarose gel containing ethidium
`bromide. After electrophoresis, the gel was photographed under ul-
`traviolet (UV) light.
`
`RAZA ET AL
`
`RESULTS
`
`Fifty patients with a confirmed diagnosis of MDS are the
`subject of this report. The French-American-British (FAB)
`classification was used to identify the various subtypes of
`MDS patients.25 There were 19 cases of refractory anemia
`(RA), 6 cases of refractory anemia with ring sideroblasls
`(RARS), 17 cases of refractory anemia with excess blasts
`(RAEB). 7 cases of RAEB in transformation (RAEB—t) and
`1 case ofchronic myelomonocytic leukemia (CMMOL). BM
`cellularity was also available in all 50 cases. Table 1 de-
`scribes the details of FAB type, apoptosis, cell cycle kinetics,
`biopsy sample cellularity and complete blood counts in all
`50 patients.
`
`Results of Control Experiments
`
`A comparison of ISEL technique with DNA ladder-ing
`detected by gel electrophoresis was performed on HL-60
`cells treated with etoposide. Whereas untreated HL-60 cells
`did not show any low molecular-weight DNA,
`the cells
`treated with etoposide showed a characteristic DNA ladder
`pattern (Fig 1A). Results obtained by lSEL correlated very
`well with these data. The percentage of apoptotic (lSEL+)
`cells in the control, untreated HL-60 cells was 1.59%.
`whereas this percentage in etoposide-treated HL-60 cells in-
`creased to 13.9% (Fig l, B and C). The DNA laddering and
`lSEL methods were similarly compared in at least three more
`sets of experiments and results obtained repeatedly showed
`that an accurate detection of apoptotic cells can be accom-
`plished using either. Once satisfied that ISEL is a highly
`accurate method of detecting PCD, we proceeded to use
`plastic embedded BM biopsy samples obtained from MDS
`patients for precise quantitation of apoptotic cell death.
`Incidence of spontaneous apoptosis was quantitatively
`scored in 20 BM biopsy samples obtained from AML pa-
`tients studied at the time of diagnosis and before receiving
`any remission induction chemotherapy. None of these biopsy
`samples showed greater than 10% to 15% of the total cells
`positive for lSEL staining. The leukemic blasts were univcr-
`sally negative. The few lSEL+ cells were usually present in
`small clusters and appeared morphologically to represent
`areas of residual normal hematopoiesis. Furthermore, dou-
`ble-labeling showed that none of the S-phase cells were
`ISEL‘.
`PCD was also studied in two normal BM biopsy samples
`obtained from NHL patients. Both the patients showed geo-
`graphically well-defined areas of apoptotic cell death scat-
`tered throughout the samples. Within these “geographically
`restricted islands of death," all three lineages of cells were
`lSEL’ , as were occasional stromal cells. On the whole, such
`areas accounted for approximately one third of thc BM bi—
`opsy sample area. but it was never as extensive as in MDS
`patients. Finally. S-phase cells were never double-labeled
`for lSEL in these samples.
`
`Proliferation Studies
`
`Statistical Analysis
`Mann Whitney tests were used for two sample comparisons of
`continuous variables. Contingency tables, with chi square statistics
`or Fisher's exact test. were used for analyzing.
`
`Sequential labeling ofS-phase cells was performed in vivo
`using infusions of IUdR and/or BrdU. Labeling indices (Ll)
`from BM biopsy samples were available in 46 patients. The
`median Ll was 28.6% with a range of 13% to 49.1%. Dura-
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 3
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 3
`
`

`

`APOPTOSIS IN 8M BIOPSY SAMPLES
`
`271
`
`Table 1. Cell Cycle Kinetics, P00, and Clinical Characteristics of Patients With MDS
`TC
`Cellularilv
`W8C Count
`Hb Count
`Platelets Count
`
`5 No.
`Patient GMA No.
`FAB
`ISEL
`LI 9L
`Ts Ihsl
`Ihsl
`(Val
`(X10’IL)
`Ig/dL)
`(x10°lLl
`1
`207/88
`HA
`High
`39.6
`15.6
`39
`30
`4.5
`11.6
`92
`2
`131/90
`RAEB-t
`High
`47
`19
`40
`15
`1.7
`12.3
`182
`3
`130/89
`FIA
`High
`26
`NA
`NA
`90
`8.4
`10.6
`433
`4
`250/87
`RA
`High
`25.1
`9.7
`38.6
`50
`2.7
`10.1
`68
`5
`14/37
`RAEB
`High
`21.3
`15.2
`17.3
`95
`12.8
`7.4
`44
`6
`3/87
`RA
`High
`15
`7.4
`47
`10
`3.9
`10.1
`29
`7
`268/90
`FIARS
`High
`29.3
`65.8
`224.6
`90
`38.1
`8.2
`360
`8
`215/90
`HARS
`High
`13
`8.06
`62
`90
`13
`9.6
`409
`9
`21/91
`RARS
`High
`37
`6.72
`18.16
`40
`4.5
`11.8
`71
`10
`43/93
`RAEB
`High
`24
`NA
`NA
`20
`0.7
`6.1
`24
`11
`11/93
`RAEB
`High
`26
`NA
`NA
`60
`3.7
`9.3
`127
`12
`5/93
`RAEB
`High
`18
`NA
`NA
`20
`1.6
`9.2
`225
`13
`63/93
`RA
`High
`25
`NA
`NA
`70
`2.9
`10.1
`256
`14
`169/90
`FIAEB-t
`High
`32
`NA
`NA
`70
`2.5
`9.3
`61
`15
`616/87
`HAEB-t
`High
`31
`22
`71
`60
`NA
`NA
`NA
`16
`390/87
`HAEB
`High
`33.6
`14.7
`43.7
`80
`14.6
`12
`219
`17
`19/93
`RAEB—t
`High
`18
`NA
`NA
`70
`10.1
`8.4
`15
`18
`21/93
`RAEB
`High
`18
`NA
`NA
`40
`1.5
`9.1
`45
`19
`20/91
`RAHS
`High
`30.6
`11.82
`38
`40
`7.5
`8.4
`417
`20
`86/94
`RA
`High
`24
`NA
`NA
`80
`3.1
`10.6
`63
`21
`98/94
`RAEB
`High
`28.7
`4.6
`16.1
`70
`4.7
`7.9
`224
`22
`150/94
`RA
`High
`31.5
`27.9
`88.6
`80
`2.5
`11.1
`162
`23
`64/94
`RAEB-t
`High
`28.5
`5.6
`19.8
`40
`1.3
`8
`25
`24
`130/94
`RAEB
`High
`24.5
`24.9
`101.8
`40
`25.7
`9.3
`43
`25
`281/94
`RAEB
`High
`18.7
`5
`27
`70
`9.8
`9.4
`99
`26
`88/94
`RAEB
`High
`23.9
`3.6
`15
`90
`1.6
`8.3
`56
`27
`382/88
`RA
`Intermediate
`46.6
`NA
`NA
`35
`NA
`NA
`NA
`28
`128/90
`RARS
`intermediate
`49.1
`6.8
`13.8
`90
`1.4
`8.3
`43
`29
`34/89
`HA
`Intermediate
`39
`24
`61.5
`65
`15.2
`9.2
`729
`30
`100/89
`fiAEB-t
`Intermediate
`39.3
`17.5
`44.5
`50
`4.9
`9.2
`32
`31
`182/80
`EARS
`Intermediate
`32.3
`16.2
`50.15
`70
`3.1
`B
`11
`32
`609/87
`HAEB-t
`Intermediate
`31
`22
`71
`50
`4
`8.8
`53
`33
`136/90
`RAEB
`Intermediate
`29
`32.3
`111.3
`60
`6.7
`8.2
`196
`34
`292/94
`RAEB
`Intermediate
`33.8
`6.9
`20.4
`80
`3.2
`9.1
`93
`35
`390/87
`RA
`Low
`33.1
`13.8
`41.7
`55
`1
`8.7
`212
`36
`74/87
`RA
`Low
`25.3
`14.6
`57.5
`50
`3.1
`10.5
`70
`37
`25/93
`RA
`LOW
`41
`NA
`NA
`70
`8.7
`9.3
`52
`38
`46/93
`RA
`LOW
`16
`NA
`NA
`30
`1.7
`7.4
`79
`39
`103/93
`RAEB
`Low
`38
`NA
`NA
`70
`0.8
`8.8
`28
`40
`26/91
`HA
`Low
`35
`5.8
`16.5
`80
`3.4
`7.8
`104
`41
`112/94
`RA
`Low
`NA
`5.3
`NA
`60
`3.7
`13.2
`126
`42
`23/94
`CMMOL
`Low
`19.1
`NA
`NA
`60
`11.8
`6.5
`173
`43
`104/94
`HA
`Low
`NA
`NA
`NA
`30
`6.3
`9.9
`30
`44
`48/94
`HAEB
`LOW
`NA
`NA
`NA
`60
`6.3
`12.8
`915
`45
`245/94
`HA
`Low
`23.9
`3
`12.6
`30
`2.5
`6.7
`52
`46
`51/93
`RAEB
`Negative
`14
`NA
`NA
`50
`3.1
`12.9
`250
`47
`68/87
`RAEB
`Negative
`24
`NA
`NA
`70
`2.5
`9.2
`1,551
`48
`282/94
`HAEB
`Negative
`24.9
`5.8
`23.1
`80
`7.4
`10
`90
`49
`275/94
`RA
`Negative
`44.5
`4.1
`9.1
`10
`1.1
`8.1
`29
`35
`50
`88/93
`RA
`NA
`NA
`NA
`NA
`1
`4
`10.9
`
`Abbreviations: GMA, glycol methacrylete biopsy; WBC, white blood cell; Hb, hemoglobin; NA, not available.
`
`tion of S-phasc (Ts) was available in 30 patients with a
`median of 12.8 hours and a range of 3.0 to 65.8 hours. Total
`cell cycle time (Tc) was available in 29 with a median of
`40.0 hours (range, 9.] to 224.6 hours). These data are also
`provided in Table 1 for individual patients.
`
`Apoptosis Studies
`
`In situ end labeling of fragmented DNA was performed
`on the plastic embedded biopsy samples of all 50 patients.
`
`A distinct brown staining in a variety of patterns over the
`nucleus identifies a cell as being engaged in DNA cleavage.
`Among the 50 cases being reported, one biopsy sample was
`excluded because of poor quality of the sample whereas four
`cases showed “absent" apoptosis or only occasional ISEL+
`cells and were considered as ISEL‘ (Table 1). Of the re-
`maining 45 cases, 26 had high. 8 had intermediate and 10
`had low ISEL-positivity.
`Interestingly, all three lineages of hematopoietic cells in-
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 4
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 4
`
`

`

`272
`
`RAZA ET AL
`
`IA) Agarou gal bloatwphorasis of DNA ox-
`Fig 1.
`tractod lrom HL-Go calls incubated wlth aloposlda at
`varylng concentrations. Lane 1, no otopoalda; lane
`2, treated with atopoalda at 11.5 umolIL for 4 noun,
`lano 3. treated wlth atopnalda at 35 pmol/L for 4
`hours; lana 4, DNA molacular-walght marker, 100-bp
`DNA ladder (GIBCO Lila Tachnologlaa, Grand Island.
`NY). Nota the appearance of Iaddarlng ln lane 3. (B)
`In situ and laballng on control HL-so calls wlthou‘l
`otopoaldo treatment show no poaltlva atalnlng. (Cl
`ISEL of atopoalda-traatad HL-60 calla show dlsfinct
`ISEL staining ovar clearly karvorrhactic calla.
`
`
`
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 5
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 5
`
`

`

`APOPTOSIS IN BM BIOPSY SAMPLES
`
`273
`
`eluding the mycloid. erythroid and megakaryocytic cells
`were found to be undergoing apoptosis. Figure ’2 shows some
`of these ISEU cells. Furthermore. almost
`in every case.
`stromal cells were also found to be apoptotic including endo-
`thelial cells. fat cells, and fibroblasts. In Figure 2, ISEL‘ as
`well as negative fibroblasts and endothelial cells can be seen.
`Figure 3 shows the typical crescent—shaped chromatin con-
`densation in an AML patient‘s leukemic blast as stained by
`the lSEL technique.
`
`Simultaneous Labeling for Proliferation and
`Apoptosis
`
`Double labeling using 1351. and anti-lUdR/BrdU antibody
`techniques was perfomted on 15 MDS patients. In every case,
`S—phuse cells were frequently found to be undergoing apoptosis
`as well. Figure 4 clearly shows a megakaryocytc that is synthe-
`sizing DNA (blue staining) and is also undergoing apoptosis
`(brown staining) or is in a state of “Antonymy.” Because all
`of the first 15 consecutive patients examined by this double—
`iabeling technique showed the same concurrent cell-birth/cell-
`death pattern, the remaining biopsy samples were not double-
`iabeled. In a number of patients, macrophages filled with lSEL’
`debris of apoptotic cells were recognizable (Fig 5).
`
`Results of DNA Laddering in MDS, AMLs, and
`Normal Controls
`
`DNA was extracted from BM asps of six MDS patients.
`(Table 1. patients no. 22, 24, 25, 34, 48. and 49), three AML
`patients and two normal individuals who were BM transplant
`donors. Figure 6 shows the results in these 11 individuals.
`Lane .1 shows the DNA molecular marker, (100-bp DNA
`ladder). The next two lattes show the results in 2 normal
`donors whose BM asps were incubated for 4 hours in com—
`plete medium before extraction of DNA. No evidence of
`DNA laddcriug can be seen in either of the normal samples.
`Similarly, the next four lattes show three AMI. patients and
`none of them show any DNA laddering either. On the other
`hand, lanes 8 through 18 represent 0- and 4—hour samples
`ot'six MDS patients. The first four ofthesc (Table 1, patients
`no. 22, 24, 25, and 34) show laddering in the 4-hour samples,
`but not in the 0-hour lanes. All 4 four 01" these individuals
`had evidence oflSliil- positivity in their biopsy samples. The
`last two MDS patients (Table 1, patients no. 48 and 49), had
`no lSEL staining in their biopsy samples and show no DNA
`laddering even after 4 hours of incubation in complete me—
`dium (lanes 15 through 18). Thus, the data obtained by gel
`electrophoresis confirmed the results obtained by lSEL stain-
`ing in all cases examined,
`
`
`
`Fig 6. Agarose gel electrophoresis of DNA extracted from Finall-
`separated BM asp mononuclear cells IBMAMNC) beiore it.) and after
`it.) incubation in RPMI 1640 medium containing 10% FBS, for 4 hours
`at 37°C. Ethldium bromide staining photographed in ultraviolet light.
`Lane 1, DNA molecular-weight markers, 100-bp DNA ladder IGIBCO
`BRL): lanes 2 and 3, 24 DNA from BMAMNC a! normal healthy donors:
`lane 4. t.; and lanes 5 through 7, t. DNA from BMAMNC of three AML
`patients; lanes 8 through 11, t. and ‘4 DNA from BMAMNC oi MDS
`patients. The normal donors as wall as AML patients did not show
`any evidence of low molecular-weight DNA at 0 or 4 hours. Interest-
`ingly, 4 of B MDS patients although showed intact DNA at 0 hours
`clearly demonstrated a characteristic laddering at 4 hours. However.
`the remnlnlng 2 MDS patients did not show Indderlng even at It
`hours. The propensity of BMAMNC to undergo apoptosis in vitro
`detected by agarose gel electrophoresis and the degree of spontane-
`ous apoptosis measured in BM biopsy samples by lSEL correlated
`very well.
`
`Other Clinical and Biologic Characteristics Versus
`Proliferation and Apoptosis
`
`The rates of cell birth and cell death were compared in
`the various FAB categories. Apoptosis was maximum in
`RAEB-t patients, all 7 having greater than 50% ISEL+ cells,
`whereas 9 RA patients had high and 9 had low lSEL-posi—
`tivity (P = .057) with two patients having intermediate posi-
`tivity. Most importantly, even though there was so much
`cell death in RAEB-t patients, clusters of lSEL' myeloblasts
`(ALIPS) were clearly recognizable. On the other hand. Ll
`was below median for 5 ul’7 RAEB—t patients, whereas half
`the RA patients had above and half had below median L1.
`lSEL results were also corelated with other parameters such
`as Ll (P = .314), T5 (P = .234), TC (P = .275), WBC (P
`—'=
`.160),
`l-lh (P = .801), platelets (P = .273), and biopsy
`sample ccllularity (P = .648). No statistically significant
`relationships were identified.
`DISCUSSION
`
`A recently described technique for detecting PCD that
`uses ISEL of fragmented DNA”” has been used in the
`
` 4
`
`Fig 2. Plastic embedded BM biopsy from an MDS patient showing large numbers of apoptotic cells labeled brown by lSEL. Note the many
`negative cells in the field. Stromal cells such as fibroblasts and andothelial cells are also ISEL‘.
`Fig 3. Chromatin condensation in the [arm of a typical crescent usually soon in earlier stages of programmed cell death stained by lSEL in
`the BM biopsy sample of a patient with acute myeioid leukemia.
`Fig 4. Double labeling to simultaneously detect calls engaged in DNA synthesis lanti-lUdR/BrdU antibody) and apoptosis (lSEL). Blue marks
`S-phase cells whereas brown marks apoptosis. Note the large megakaryocyte that is simultaneously engaged in both processes (blue and
`brown staining). This state has been termed "Antonymy."
`Fig 5. A macrophage that contains lSEL‘ debris of apoptutic cells in the BM biopsy sample oI an RAEB-t patient.
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 6
`
`DR. REDDY’S LABS., INC. EX. 1018 PAGE 6
`
`

`

`274
`
`RAZA ET AL
`
`present study to determine the incidence of intrarnedullary
`cell death in patients with tnyelodysplastic syndromes. Four
`unique observations have been made in the present study.
`First, that myclodysplastic syndromes are highly prolifera-
`tive disorders with almost one third of the marrow cells
`engaged in DNA synthesis (median Ll for myeloid cells,
`29%; median cell cycle time, 44 hours). Second, that unfortu-
`nately this high rate of cell birth is cancelled by an equally
`high rate of cell-death resulting in a functionally aplastic
`BM, an observation that constitutes the most likely basis for
`the apparent paradox of pancytopenia despite hypercellular
`marrows encountered in the majority of these patients. This
`high rate of apoptosis affected not only all three lineages of
`the hematopoietic cells, but also involved cells of stromal
`origin (fat cells, endothelial cells, fibroblasts). Third,
`that
`many cells are simultaneously engaged in DNA synthesis
`and apoptosis. Fourth, that the DNA extracted immediately
`upon density separation of BM asps showed no laddering in
`agarose gels, whereas DNA extracted after a 4-hour incuba-
`tion of density-separated cells in complete medium showed
`the characteristic laddering in 4 of 4 MDS patients with
`250% ISEL” cells in the matched biopsy samples, but none
`in the 2 of 2 MDS patients with no ISEL staining in their
`biopsy samples.
`While a high rate of apoptosis has previously been hypoth-
`esized to be a possible explanation for the ineffective hema-
`topoiesis observed in these disorders on the basis of finding
`increased apoptotic nuclei in trephine sections,” the present
`rcpor1 is the first documented proof that large numbers of
`marrow cells are engaged in earlier stages of PCD. Several
`features of this study are unexpected. To begin with,
`the
`extent of apoptosis encountered was previously unsuspected.
`In 26 of

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket